-
1 Comment
DexCom, Inc is currently in a long term uptrend where the price is trading 19.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.1.
DexCom, Inc's total revenue rose by 22.9% to $569M since the same quarter in the previous year.
Its net income has increased by 283.2% to $355M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.2% to $112M since the same quarter in the previous year.
Based on the above factors, DexCom, Inc gets an overall score of 5/5.
Industry | Medical Devices |
---|---|
Exchange | F |
ISIN | US2521311074 |
Sector | Healthcare |
CurrencyCode | EUR |
Beta | 1.5 |
---|---|
Market Cap | 24B |
PE Ratio | 48.63 |
Target Price | 530.6 |
Dividend Yield | None |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for DC4.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025